Assessing the need for rebiopsy in patients with elevated serum PSA levels and a negative diagnosis of prostate cancer following analysis of the initial biopsy sample is a challenging, and often frustrating, clinical scenario. Here, authors describe the clinical utility of a range of approaches to guiding the need for rebiopsy, whilst also highlighting the diagnostic value of combining results of multiple tests.
- Michael L. Blute Jr
- E. Jason Abel
- David F. Jarrard
